Matinas Biopharma (NYSE:MTNB) is a clinical-stage biopharmaceutical company specializing in the development of novel lipid-based drug products that enhance the delivery and efficacy of existing therapies. Leveraging its proprietary Lipid NanoCrystal (LNC) platform, Matinas focuses on improving the bioavailability and targeted delivery of pharmaceutical compounds, particularly in the areas of anti-infectives and cardiovascular disease. The company’s mission is to address unmet medical needs by transforming how drugs are formulated and administered.
The company’s lead product candidate, MAT2203 (formerly iCo-010), is an oral formulation of amphotericin B designed to treat life-threatening fungal infections such as cryptococcal meningitis. Preclinical and early clinical data suggest that MAT2203 may offer improved tolerability and reduced toxicity compared to current intravenous formulations, potentially enabling outpatient treatment. In addition to its antifungal franchise, Matinas is advancing lipid-based formulations of omega-3 fatty acids for cardiovascular health, seeking to optimize absorption and dosing convenience.
Founded in 2014 and headquartered in Bedminster, New Jersey, Matinas Biopharma operates research and development facilities in the United States and collaborates with academic institutions and contract research organizations worldwide. The company holds a portfolio of patent families covering its LNC platform and specific drug candidates, and it continues to explore partnerships that can accelerate clinical development and regulatory approval across multiple therapeutic areas.
Matinas Biopharma’s leadership team combines expertise in pharmaceutical development, regulatory affairs, and commercial strategy. Chief Executive Officer John H. Johnson, Ph.D., brings more than two decades of experience in drug discovery and product development, while Chief Financial Officer Tracey Franklin oversees corporate finance and investor relations. The company’s governance structure includes a board of directors with seasoned industry veterans who guide Matinas through its clinical trials and toward potential commercialization.
